Huasen Pharmaceutical (002907.SZ): Phosphate ORIC-1327 eye drops have received approval for clinical trials.

According to the report fromAPP, Huasen Pharmaceutical (002907.SZ) announced that its holding subsidiary Chengdu Huasen Aori Pharmaceutical Co., Ltd. (hereinafter referred to as "Huasen Aori") recently received the "Approval Notice for Drug Clinical Trials" issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for the phosphoric acid ORIC-1327 eye drops, which corresponds to 6 specifications for 2 indications.